Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Histidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 known ✓ | Q9Y5N1 | 3/20 | 0.59 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.97 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | APEX1 | P27695 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | THPO | P40225 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Histidine SCHEMBL209484 | 1.00 | CYP3A4 (0.97) | CYP3A4SLC7A5ALDH1A1HRH4HRH3 | |
| D-Histidine SCHEMBL8002459 | 1.00 | CYP3A4 (0.97) | CYP3A4SLC7A5ALDH1A1HRH4HRH3 | |
| Histidine SCHEMBL3985699 | 1.00 | CYP3A4 (0.97) | CYP3A4SLC7A5ALDH1A1HRH4HRH3 | |
| Histidine SCHEMBL16893960 | 1.00 | CYP3A4 (0.97) | CYP3A4SLC7A5ALDH1A1HRH4HRH3 | |
| Histidine SCHEMBL5134199 | 1.00 | CYP3A4 (0.97) | CYP3A4SLC7A5ALDH1A1HRH4HRH3 | |
| D-Histidine SCHEMBL3639231 | 0.98 | CYP3A4 (0.93) | CYP3A4SLC7A5ALDH1A1HRH4HRH3 | |
| Histidine SCHEMBL1705391 | 0.98 | CYP3A4 (0.93) | CYP3A4SLC7A5ALDH1A1HRH4HRH3 | |
| Histidine SCHEMBL31618930 | 0.98 | CYP3A4 (0.93) | CYP3A4SLC7A5ALDH1A1HRH4HRH3 | |
| Histidine SCHEMBL29250215 | 0.98 | CYP3A4 (0.93) | CYP3A4SLC7A5ALDH1A1HRH4HRH3 | |
| Histidine SCHEMBL28330064 | 0.98 | CYP3A4 (0.93) | CYP3A4SLC7A5ALDH1A1HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013024028-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING PROTEINOPATHIES | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2013-02-21 | — | — | WO | claimed |
| US-20100130416-A1 | MODULATION OF ANGIOGENESIS BY A-BETA PEPTIDE FRAGMENTS | ARCHER PHARMACEUTICALS, INC. (US) | 2010-05-27 | — | — | US | claimed |
| WO-2009143489-A2 | MODULATION OF ANGIOGENESIS BY A-BETA PEPTIDE FRAGMENTS | ARCHER PHARMACEUTICALS, INC. (US) | 2009-11-26 | — | — | WO | claimed |
| EP-0456806-B1 | HISTIDINE BUFFERED PERITONEAL DIALYSIS SOLUTION | BAXTER INT (US) | 1996-12-11 | — | — | EP | claimed |
| US-4035513-A | COSMETICS | SHISEIDO CO., LTD. (JA) | 1977-07-12 | — | — | US | claimed |
| US-9976163-B2 | Method for preventing reduction of polypeptide by adding amino acid to culture solution | KYOWA HAKKO KIRIN CO., LTD (JP) | 2018-05-22 | — | — | US | disclosed |
| CN-106176730-A | The amino acid whose medical composition and its use of 9AA containing chiral photo-isomerisation compound | 刘力 | 2016-12-07 | — | — | CN | disclosed |
| US-20150275259-A1 | METHOD FOR PREVENTING REDUCTION OF POLYPEPTIDE BY ADDING AMINO ACID TO CULTURE SOLUTION | KYOWA HAKKO KIRIN CO., LTD (JP) | 2015-10-01 | — | — | US | disclosed |
| EP-2905342-A1 | METHOD FOR PREVENTING POLYPEPTIDE REDUCTION BY ADDING AMINO ACID TO LIQUID CULTURE MEDIUM | Kyowa Hakko Kirin Co., Ltd. (JP) | 2015-08-12 | — | — | EP | disclosed |
| WO-2013024028-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING PROTEINOPATHIES | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2013-02-21 | — | — | WO | disclosed |
| US-20110182877-A1 | SUSTAINED DELIVERY OF COMPSTATIN ANALOGS FROM GELS | POTENTIA PHARMACEUTICALS, INC. (US) | 2011-07-28 | — | — | US | disclosed |
| EP-2207530-A2 | SUSTAINED DELIVERY OF COMPSTATIN ANALOGS FROM GELS | Potentia Pharmaceuticals, Inc. (US) | 2010-07-21 | — | — | EP | disclosed |
| US-6403806-B1 | FORMING HISTAMINE MONOHYDROCHLORIDE CONTAINING SOLUTION FROM DECARBOXYLATED L-HISTIDINE-CONTAINING SOLUTION BY ADDITION OF HYDROGEN CHLORIDE, FORMING HISTAMINE DIHYDROCHLORIDE CONTAINING SOLUTION BY FURTHER ADDITION OF HYDROGEN CHLORIDE | MAXIM PHARMACEUTICALS, INC. | 2002-06-11 | — | — | US | disclosed |
| US-20020035268-A1 | Synthesis of histamine dihydrochloride | CYTOVIA, INC. | 2002-03-21 | — | — | US | disclosed |
| EP-1140857-A1 | SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE | Maxim Pharmaceuticals, Inc. (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000039098-A1 | SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE | MAXIM PHARMACEUTICALS, INC. (US) | 2000-07-06 | — | — | WO | disclosed |
| EP-0456806-B1 | HISTIDINE BUFFERED PERITONEAL DIALYSIS SOLUTION | BAXTER INT (US) | 1996-12-11 | — | — | EP | disclosed |
| US-5092838-A | HISTIDINE BUFFERED PERITONEAL DIALYSIS SOLUTION | BAXTER INTERNATIONAL INC. (US) | 1992-03-03 | — | — | US | disclosed |
| WO-1991008008-A2 | HISTIDINE BUFFERED PERITONEAL DIALYSIS SOLUTION | BAXTER INTERNATIONAL INC. (US) | 1991-06-13 | — | — | WO | disclosed |
| US-4549427-A | Electronic nerve agent detector | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE (US) | 1985-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130416-A1 | MODULATION OF ANGIOGENESIS BY A-BETA PEPTIDE FRAGMENTS | VEGFA, APP, IAPP | HRH3 3203/4885GLA 243/4885CYP3A4 4855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.